达格列净对射血分数降低心力衰竭患者肾功能及结局的疗效:DAPA-HF研究结果
DAPA-HF试验纳入4742例HFrEF患者(伴或不伴2型糖尿病,eGFR≥30 mL·min⁻¹·1.73 m⁻²),按基线eGFR分层分析。结果显示基线肾功能不影响达格列净对主要复合终点(心血管死亡或心衰恶化)的获益,且达格列净减缓eGFR下降速率,非糖尿病患者同样获益。
要点
- 基线肾功能不影响达格列净对HFrEF患者发病率和死亡率的获益。
- 达格列净减缓eGFR下降速率,非糖尿病患者同样获益。
- 复合肾脏结局未达统计学显著差异。
核心结论
- 基线肾功能未改变达格列净对HFrEF患者发病率和死亡率的获益。
- 达格列净减缓eGFR下降速率,包括非糖尿病患者。
研究设计与样本
- DAPA-HF试验的事后分析,纳入4742例HFrEF患者(伴或不伴2型糖尿病,eGFR≥30 mL·min⁻¹·1.73 m⁻²)。
- 按基线eGFR分类(<60和≥60 mL·min⁻¹·1.73 m⁻²)及连续变量分析达格列净的疗效。
主要发现
- 1926例(41%)患者基线eGFR<60 mL·min⁻¹·1.73 m⁻²。
- 慢性肾脏病患者的首要终点风险比(95%CI)为0.71(0.59-0.86),eGFR≥60组为0.77(0.64-0.93),交互作用P=0.54。
- 复合肾脏结局风险比=0.71(95%CI 0.44-1.16),P=0.17。
- 第14天至720天eGFR下降速率:达格列净组-1.09(-1.40至-0.77) vs 安慰剂组-2.85(-3.17至-2.53) mL·min⁻¹·1.73 m⁻²/年,P<0.001。
- eGFR下降速率的减缓在伴或不伴2型糖尿病患者中均观察到达(交互作用P=0.92)。
临床怎么用
- HFrEF患者无论基线肾功能如何均可考虑使用达格列净以降低心血管死亡和心衰恶化风险。
- 达格列净可减缓eGFR下降,支持在慢性肾脏病合并HFrEF患者中使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Many patients with heart failure and reduced ejection fraction (HFrEF) have chronic kidney disease that complicates pharmacological management and is associated with worse outcomes. We assessed the safety and efficacy of dapagliflozin in patients with HFrEF, according to baseline kidney function, in the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-outcomes in Heart Failure). We also examined the effect of dapagliflozin on kidney function after randomization. METHODS: Patients who have HFrEF with or without type 2 diabetes and an estimated glomerular filtration rate (eGFR) ≥30 mL·min-1·1.73 m-2 were enrolled in DAPA-HF. We calculated the incidence of the primary outcome (cardiovascular death or worsening heart failure) according to eGFR category at baseline (<60 and ≥60 mL·min-1·1.73 m-2) and used eGFR at baseline as a continuous measure, as well. Secondary cardiovascular outcomes and a prespecified composite renal outcome (≥50% sustained decline eGFR, end-stage renal disease, or renal death) were also examined, along with a decline in eGFR over time. RESULTS: Of 4742 patients with a baseline eGFR, 1926 (41%) had eGFR <60 mL·min-1·1.73 m-2. The effect of dapagliflozin on the primary and secondary outcomes did not differ by eGFR category or examining eGFR as a continuous measurement. The hazard ratio (95% CI) for the primary end point in patients with chronic kidney disease was 0.71 (0.59-0.86) versus 0.77 (0.64-0.93) in those with an eGFR ≥60 mL·min-1·1.73 m-2 (interaction P=0.54). The composite renal outcome was not reduced by dapagliflozin (hazard ratio=0.71 [95% CI, 0.44-1.16]; P=0.17) but the rate of decline in eGFR between day 14 and 720 was less with dapagliflozin, -1.09 (-1.40 to -0.77) versus placebo -2.85 (-3.17 to -2.53) mL·min-1·1.73 m-2 per year (P<0.001). This was observed in those with and without type 2 diabetes (P for interaction=0.92). CONCLUSIONS: Baseline kidney function did not modify the benefits of dapagliflozin on morbidity and mortality in HFrEF, and dapagliflozin slowed the rate of decline in eGFR, including in patients without diabetes. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03036124.
引用
- Jhund PS, Solomon SD, Docherty KF, et al. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF. Circulation. 2020. PMID: 33040613. doi:10.1161/CIRCULATIONAHA.120.050391
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。